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Abstract
Background: The rapid growth of health care expenditures, especially pharmaceutical spending, is a challenge for
many countries. To control increasing pharmaceutical expenditures and to enhance rational use of drugs, Taiwan’s
National Health Insurance drug reimbursement system has evolved over time since its introduction in 1995. This
study reviewed Taiwan’s drug reimbursement scheme: its development and evolution in the last two decades, and
implications and impacts of recent policies for drug pricing. We also provide recommendations for possible
improvement.
Methods: We conducted a review of Taiwan’s National Health Insurance drug reimbursement scheme. We focused
on three major components of the scheme: (i) the scope of drug coverage; (ii) pricing system for pharmaceuticals
under the scheme; and (iii) adjustment of drug reimbursement prices. We reviewed the literature and public policy
documents.
Results: The National Health Insurance delisted 176 and another 240 behind-the-counter products (e.g., antacids,
vitamins) between 2005 and 2006 to reduce pharmaceutical expenditures. For the pricing of pharmaceuticals, policy
evolution can be divided into four phases since 1995; the present system emphasizes stakeholder engagement,
health technology assessment, domestic R&D, and improving quality of products. To close the gap between drug
reimbursement prices and procurement prices, eight rounds of drug price surveys and adjustments have been
implemented since 2000.
Conclusions: Taiwan’s National Health Insurance drug reimbursement scheme has evolved substantially over time
to provide more equitable and affordable access to prescription medicines. However, more work is still needed as
irrational difference in reimbursement and procurement prices persists and the total expenditure of the drug
reimbursement scheme continues to increase at unsustainable rates.
Keywords: Universal health coverage, Drug policy, Reimbursement, Medicines coverage, National Health Insurance,
Taiwan
Introduction
Access to health care, including ‘essential’ medicines, is
regarded as a human right by the International Covenant
on Economic, Social and Cultural Rights [1]. The vast
majority of people and governments around the world
generally support the implementation of national health
insurance. Many economically developed countries have
implemented national health insurance that aims to pro-
vide its members with satisfactory care services to achieve
“health for all” [2]. However, many healthcare systems
have sometimes achieved poor performance given the re-
sources spent and/or are still undergoing reform.
In Taiwan, the National Health Insurance (NHI) is a
compulsory social insurance system in which the coverage
rate of its 23 million residents is as high as 99% currently.
Since the introduction in August 1995, the National
Health Insurance has gained public recognition as Taiwan
becomes comparable with neighboring countries (like
Japan, South Korea and Singapore) in terms of quality of
care, healthcare cost control, drug spending growth, and
public satisfaction [3]. However, concerns have been raised
about its financial sustainability.
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Around the world, countries generally adopt a pluralistic
system of healthcare coverage that maximizes consumer
choice (e.g., USA) or a predominantly single, universal
scheme for healthcare coverage that maximizes equity and
the prospects for cost control. Taiwan adopts the single sys-
tem model. The National Health Insurance is contracted
with public, private, and corporate healthcare institutions,
which provide a range of covered healthcare services, in-
cluding prescription drugs. The National Health Insurance
Administration (NHIA; formerly known as the Bureau of
NHI, the name was changed in 2013), set up by the govern-
ment, reimburses the contracted institutions for the ser-
vices provided.
The rapid growth of healthcare costs is a challenge
faced by all countries, especially the growth of pharma-
ceutical costs, which is even more evident [4,5]. The
total drug expenditure of Taiwan’s National Health In-
surance was about US$2,133 million in 1997, and it in-
creased by around US$173 million each year. In 2012,
pharmaceutical expenditures reached US$4,733 million,
which accounted for 25.1% of the total healthcare expend-
iture (Figure 1) [3]. The main causes of rising healthcare
costs and pharmaceutical expenditures include the
aging population, the increasing number of patients
with chronic diseases, increasing drug prices, larger
drug usages, and the availability of new, more expensive
drugs [6-8].
To control growing pharmaceutical expenditures, the
NHIA implemented multiple policies for prescription
drug reimbursement. The purpose of this study was to re-
view and summarize the evolution of Taiwan’s drug reim-
bursement scheme over the last two decades, including its
development and major changes for drug pricing, and im-
plications and impacts of its recent policies. We also
highlighted possible policy-induced problems that need to
be addressed. Finally, we provide some recommendations
for how Taiwan’s drug reimbursement scheme can con-
tinue to evolve to ensure the goals of financial sustainabil-
ity and rational use of medicines [9].
Method
We conducted a review of Taiwan’s National Health
Insurance drug reimbursement scheme. We focused
on policies implemented by the NHIA over the last
two decades. We reviewed policies that targeted differ-
ent issues: (1) the scope of drug coverage, (2) the pri-
cing system for pharmaceuticals under the scheme,
and (3) adjustments of drug reimbursement prices.
Similar to many countries, medicines are classified into
three categories in Taiwan: (a) prescription drugs, (b)
drugs designated by physicians or pharmacists, which
can be purchased at pharmacies without prescriptions
(e.g., antihistamines, antitussive agents) – generally known
as behind-the-counter or pharmacist only drugs, and (c)
over-the-counter (OTC) medications.
We collected and reviewed historical archives including
official documents, books, published articles, research pro-
jects, conference records, websites, newspapers, speeches
etc. After reviewing abovementioned materials relating to
the drug reimbursement scheme, we also examined policy
implementation and policy changes, summarized the known
impacts of the policies, and highlighted possible policy-
induced problems that need to be addressed for system
improvement.
Year
Figure 1 The evolution of drug reimbursement expenses. *Rate of Drug Expenses (%): proportion of drug expenditure of total health care costs.
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Results
NHIA policies over the last two decades largely targeted
prescription drugs and behind-the-counter drugs.
Policies governing the scope of drug coverage
According to Article 51 in the National Health Insurance
Act (amended in 2011) [10], the NHIA does not reim-
burse the following: (1) medicines that are approved by
the Taiwan Food and Drug Administration (Taiwan FDA)
but are not used for disease treatment, such as contracep-
tive, hair tonic, dark spots detergent, smoking cessation
patches; (2) some vaccines (e.g., quadrivalent Human pap-
illomavirus types vaccine); (3) over-the-counter drugs and
non-prescription drugs which should be used under the
guidance of a physician or pharmacist (also called the
behind-the-counter drugs); (4) drugs for human-subject
clinical trials; (5) drugs which are deemed by the National
Health Insurance as not essential for medical treatment
(e.g. dentures, artificial eyes, spectacles, hearing aids,
wheelchairs, canes, and other treatment equipment) or
not cost-effective; (6) drugs which do not conform to
the indication that stipulated in the approved indication
for licensing and/or the “Reimbursement Restriction”
enacted by the National Health Insurance. However, in
special cases, an application for prior authorization can
be made to the National Health Insurance, and the
drug will be reimbursed if authorization is given; and
(7) any other drug which the NHIA publicly announces
that it will not be reimbursed [11].
Behind-the-counter drugs were covered by the former
Civil Servant Insurance and Labor Insurance and in the
early years of the National Health Insurance. The NHIA
reviewed and reduced the scope of coverage of behind-
the-counter drugs over time [11]. Some behind-the-
counter drugs were delisted to meet the priorities of the
National Health Insurance, in accordance with Article
51 of the National Health Insurance Act, and more gen-
erally, to establish patient expectations and the culture
of rational use of medicines and basic self-healthcare.
This change also intended to reduce costs of the
National Health Insurance as well as making better use
of its resources for treatment of major diseases.
This delisting of behind-the-counter drugs also bene-
fited consumers who needed such products for treat-
ment of minor illnesses (e.g., headache, cold). They can
save time and related expenses when they choose to pur-
chase medicines at pharmacies instead of visiting physi-
cians at primary care clinics or hospitals. For example, a
patient’s out-of-pocket costs are less if s/he chooses to
purchase medicines for headache from pharmacies (only
US$3) compared with visiting a physician which requires
physician visit copays (US$5).
In total, the National Health Insurance delisted 176 (e.g.,
some antacids) and 240 (e.g., some vitamins, electrolytes)
behind-the-counter products in 2005 and 2006 respect-
ively. However, there was considerable resistance from
both physicians and patients; thus, no further behind-
the-counter drugs were delisted. Currently, there are
still around 1400 behind-the-counter products reim-
bursed by NHIA (e.g., gastrointestinal drugs, antihista-
mines, antitussive agents) [3]. However, delisting in the
future is likely under the pressure to contain costs.
The pricing system for pharmaceuticals under the drug
reimbursement scheme
The pricing system under the drug reimbursement scheme
of the National Health Insurance can be divided into four
phases over time: (1) internal audit price (1995/3-1997/3);
(2) uniform pricing (1997/4-1999/2); (3) Pharmaceutical
benefit scheme (1999/3-2012/12); and (4) Pharmaceutical
benefits and reimbursement schedule (after 2013/1), which





Internal audit price phase
Uniform price phase
Pharmaceutical benefit scheme
Pharmaceutical benefits and          
reimbursement schedule
Figure 2 The evolution of drug pricing of the drug reimbursement scheme under Taiwan’s National Health Insurance.
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Prior to the implementation of the National Health
Insurance in 1995 in Taiwan, about 50% of the popula-
tion was insured under the Civil Servant Insurance,
Labor Insurance, and Farmer’s Health Insurance. At the
time, pharmaceutical companies were allowed free pri-
cing, and they were subject to hospitals’ pharmaceutical
tender and negotiation to determine the price of drugs
in hospitals. Hospitals would bill the insurers. The in-
surers would then reimburse individual hospitals by an
approach known as “transaction cost-plus”. For drug
reimbursements, the joint bid price would be paid to
public hospitals while to this price plus 10-20% would
be paid to private hospitals. Profits were usually used to
pay for drug warehouse management, dispensing and
other expenses. High-level hospitals tended to use more
expensive, brand-name drugs or imported drugs be-
cause of profits from pharmaceutical sales. At the time
of public bidding in public hospitals, manufacturers
were reluctant to cut prices, resulting in high tender
prices. Prescription drugs were paid out-of-pocket in
primary care settings because most patients were not
insured under the Government Employee’s Insurance,
Laborer Insurance, or Farmer’s Health Insurance. As a
result, patients were sensitive to drug prices; many
would choose domestic, generic drugs over the more
expensive, brand-name drugs or imported drugs.
At the early stage of the National Health Insurance
(1995–1997), the NHIA released the “National Health
Insurance Drug Items Table” that listed products being
covered, and drugs were reimbursed through the “in-
ternal audit pricing” approach. However, the internal
audit pricing system was unclear, and the price of
imported generic drugs was relatively high due to a lack
of international drug price comparison. These led to
substantial variations in drug prices between domestic
drugs and drugs by international manufacturers [12].
Hospitals generally adopted the “fee for service” ap-
proach for drug reimbursements while primary care
clinics adopted the “fixed fees by days of supply” ap-
proach (e.g., one-day supply of any medications received
a reimbursement of NT$35, regardless therapeutic indi-
cation and actual procurement price; two-day supply
was NT$70; and three-day supply was NT$100). The
following ‘consequences’ were observed: (1) primary
care clinics tended to reduce drug costs and were reluc-
tant to release prescriptions to patients so patients had
to obtain drugs at the clinics (resulting in the phenomenon
of “next-door pharmacy”, which had negative impacts
on the separation of drug prescribing and dispensing);
(2) some patients were transferred to higher level
hospitals in order to obtain drugs of higher prices and/
or for longer supplies; and (3) use of drugs of higher
prices in primary care clinics was subsequently reduced
[13,14].
During 1997–1999, the NHIA invited the pharmaceut-
ical industry to engage in the development of pricing
guidance for drugs covered under the NHI (“National
Health Insurance drug pricing principles”). The goals
were to lower drug prices, control the growth of drug
prices, reduce the prices of brand-name drugs and gen-
eric drugs, encourage the use of generic drugs, and pro-
tect the domestic generic drug market. The pricing
guidance governed drug pricing by a drug classification
system: (1) new drugs: the NHIA invited the medical
and pharmaceutical experts to engage in the review and
approval process; (2) the compound and special specifi-
cation drugs: paid the same minimum price as other
drugs of the same composition; (3) brand-name drugs:
brand-name drugs were subdivided into two categories:
ones that have no bioavailability/bioequivalence (BA/BE)
generic drugs as alternatives in the market, and others
that have BA/BE generic drugs as alternatives. Drugs of
the former category were priced according to the inter-
national drugs with average market prices; while the
price of the latter category must not exceed 85% of the
average market price of international drugs; (4) the price
of BA/BE generic drugs must not exceed the price of
brand-name drugs; and (5) the price of non-BA/BE
generic drugs must not exceed 80% of the price of
brand-name drugs. From then on, drugs covered by the
National Health Insurance were uniformly priced.
During 1999–2012, the NHIA attempted to address
the problem of differences between drug procurement
and reimbursement prices. To determine the market
drug price difference, the NHIA required hospitals and
manufacturers to provide the actual transaction prices
and trading volumes. However, many hospitals and man-
ufacturers resisted such investigation or supplied false
declarations about prices, and the drug price gap remained
a serious problem. The NHIA therefore announced the
“Pharmaceutical Benefits Scheme” in March 1999 to gov-
ern the listing of drugs, the pricing of pharmaceuticals,
and the adjustment of drug reimbursement prices. It also
set the target to reduce the gap in drug prices to less than
15% within five years. Moreover, NHIA announced in
April 1999 that drug price surveys for NHI reimbursed
drugs were to be conducted every 1–2 years. Since then,
the NHIA has implemented eight drug price surveys; new
drug reimbursement prices were announced and imple-
mented respectively on April 1st, 2000, April 1st, 2001,
March 1st, 2003, September 1st, 2005, November 1st, 2006,
October 1st, 2009, November 1st, 2011 and May 1st, 2014
(Table 1) [15]. Adjustments of drug prices are discussed in
detail in the next section.
The “Pharmaceutical Benefit Scheme” was replaced by
“Pharmaceutical benefits and reimbursement schedule”
on January 1st, 2013. Compared with “Pharmaceutical
Benefit Scheme”, the present new scheme emphasizes
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stakeholder engagement (including the insurer and the
relevant authorities, experts and scholars, the insured,
employers, health care service providers, etc.) to discuss
and design the listing of drugs and reimbursement prices
for specific products. Further, health technology assess-
ment (considering human health, medical ethics, cost-
effectiveness of products, and financial sustainability of
the NHI) was required for new drugs prior to listing in
the National Health Insurance under this new phase. In
2007, the Center for Drug Evaluation (CDE) was created
to conduct health technology assessment (HTA), that is,
assessment of comparative efficacy, cost-effectiveness, and
budget impact of new drugs. The CDE only provides HTA
reports to the NHIA, it is not involved in pricing. The
NHIA considers HTA evidence as part of the information
used for listing and reimbursement decisions [16].
The adjustment of drug reimbursement prices
To ensure reasonable drug prices and close the gap be-
tween procurement and insurer reimbursement prices
for prescription drugs, Taiwan made multiple efforts. Be-
cause institutions procure large quantities of medicines,
procurement prices are typically lower than the amount
reimbursed by the NHIA and the differences constitutes
a profit for hospitals [17]. To assess procurement prices,
the NHIA conducted surveys to obtain drug wholesale
prices from pharmaceutical companies and procurement
prices from hospitals since 1999 [18]. Reimbursements
were adjusted if there was a difference of 30% or more
between the average procurement price and the NHI re-
imbursed price. Prices were subsequently monitored and
adjusted every two years for patented products, for prod-
ucts whose patent right has expired for more than five
years, and for products that have no patent right. These
drugs are further divided into the following two categories:
(1) drugs from original R&D pharmaceutical companies,
drugs of which the process of pharmaceutical form com-
plies with “The Pharmaceutical Inspection Convention
and Pharmaceutical Inspection Co-operation Scheme -
Good manufacturing practice (PIC/S GMP)” require-
ments, BA/BE generic drugs, drugs approved to by the US
FDA and/or The European Medicines Agency for market-
ing, controlled items of BE generic drugs; (2) common
generic drugs which do not fall into the first category [11].
Studies have been conducted to examine effects of
drug reimbursement price reductions in Taiwan. Lee
et al. [19] assessed the effects of six drug price policies
and found that they reduced pharmaceutical expendi-
tures, especially for outpatient medications and for hospi-
tals (compared with clinics) [19]. Chen et al. [17] showed
that reimbursement price reductions for targeted cardio-
vascular medications reduced the daily medical use and
expenditures, but did not affect non-targeted products
[17]. Chu et al. [20] studied price reductions for anti-
hypertensive drugs. They suggested that reimbursement
price adjustments may have created an incentive for phy-
sicians to prescribe drugs with higher profit margins, and
to increase prescription duration or the number of drug
items per prescription [20]. Hsiao et al. [21] did not find
strong associations between reimbursement price adjust-
ments and drug utilization and expenditures during
2001–2004. Chu et al. [22] studied effects of reimburse-
ment price adjustments on outpatient hypertension treat-
ments among the elderly. They found that the average
cost per prescription increased slightly, and that physi-
cians tended to prescribe drugs whose prices were not re-
duced instead of those subject to price reductions.
Findings by Hsu et al. [18] indicated that prescribing
shifted from targeted to non-targeted products [18]. Over-
all, these studies suggest shifts in use from targeted to
non-targeted products to maintain profits from drug price
gaps but whether they reduced pharmaceutical expendi-
tures is unclear.
Discussion
The study provides a review of the development and evolu-
tion of Taiwan’s universal drug reimbursement scheme
under its National Health Insurance. We highlighted major
policy changes for drug pricing over the last two decades
and their known impacts and implications. It is important
to note that many policy changes (e.g., delisting of behind-
the-counter products, introduction of HTA) remain to be
evaluated for their impacts on medication use, drug prices,
quality of care, and pharmaceutical expenditures.
With the goal to reduce pharmaceutical expenditures
to the government, about 400 behind-the-counter prod-
ucts were delisted from Taiwan’s national Drug Reim-
bursement Scheme. This coverage change also aimed to
establish patient expectations and the culture of rational
use of medicines and basic self-healthcare for minor ill-
nesses such as headache or cold. This is not surprising;
many national drug coverage schemes do not reimburse
or reimburse only selected few behind-the-counter products,
e.g., Australia’s Pharmaceutical Benefits Scheme. Misuse,
under-use or over-use of behind-the-counter drugs are
Table 1 List of drug price surveys and adjustments
Order Date Estimated cost-savings (million US$)
1st April 1st, 2000 16.67
2nd April 1st, 2001 153.33
3rd March 1st, 2003 190.00
4th September 1st, 2005 81.00
5th November 1st, 2006 500.00
6th October 1st, 2009 195.67
7th November 1st, 2011 –
8th May 1st, 2014 –
Resource: Huang [15].
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possible unintended consequences. Inappropriate consumer
self-medication may lead to subsequent medication-related
adverse health outcomes (e.g., medication error or poison-
ing), or negative health outcomes if appropriate treatment
was delayed or not used, which may lead to subsequent in-
crease in healthcare costs. It is important that delisting of
behind-the-counter medications is accompanied by appro-
priate educational programs directed to consumers and
pharmacists to ensure rational use of medicines. Taiwan may
learn from Australia, which has worldly recognized multifa-
ceted programs to improve rational use of medicines [23].
To ensure reasonable drug prices and close the gap
between procurement and insurer reimbursement prices
for prescription drugs, Taiwan and other countries (e.g.,
China) [24] have made multiple efforts. We highlighted
how the pricing system under Taiwan’s Drug Reimburse-
ment Scheme has evolved over time. While the gap be-
tween drug procurement and reimbursement prices has
narrowed, price difference persists. For instance, there
are substantial price difference between drug reimburse-
ments and claims made by primary care clinics for pre-
scription drugs that use the “fixed fees by days of
supply” approach mentioned above.
Whether drug price adjustments achieved the intended
cost-savings is unclear. Despite several waves of drug
price adjustments to close the gap between procurement
and reimbursement prices, the total pharmaceutical ex-
penditures is still on the rise (average yearly growth rate
for pharmaceutical expenditures from 1997 to 2012 is
8.13%). Reasons for such growth include: (1) adjust-
ments of drug reimbursement prices only reduce the
prices of targeted products, not the volume of use; (2)
off-label use: it has not been estimated how much expendi-
tures are attributed to use of prescription medications out-
side approved indications under the Drug Reimbursement
Scheme; reimbursed indications are largely based on
clinical treatment guidelines, Taiwan FDA approved in-
dications and specification made by NHIA or medical
associations; (3) drug waste (unnecessary use and stock-
piling of medications): this issue is particularly common
for behind-the-counter drugs (e.g., antacid agents and
vitamins), which led to delisting of some products by
the NHI; however, delisting was opposed by many phy-
sicians and patients; and (4) the availability of innova-
tive, expensive drugs such as cancer targeted therapies:
the NHI created the HTA body to assess the cost-
effectiveness of new drugs to inform decisions about
reimbursement.
We recommend that capitation/case payment models
[25], diagnosis related groups (DRGs) [26-28] and pay for
performance [29,30] are some possible alternative ap-
proaches, that have been used by other countries and show
promise in controlling total pharmaceutical expenditures
without substantially reducing the quality of health care.
Health Technology Assessment is increasingly adopted
for making drug reimbursement decisions throughout
the Asia-Pacific markets. Apart from Taiwan, countries
in this region with established HTA system include
Australia, New Zealand, South Korea, and Thailand
[31,32]. Economic evaluation should not only inform the
decision of reimbursement but also used to negotiate
prices with manufacturers. In addition, many countries
(including countries in Asia-Pacific markets such as
Australia, South Korea) are adopting risk-sharing agree-
ments for funding high-cost innovative drugs such as
adalimumab and imatinib. Risk-sharing agreements are
typically between a payer and a pharmaceutical company
in which the partners negotiate the price of a product
and/or the overall spending depending on volumes sold,
clinical outcomes achieved or patient populations who
receive the drug [33-35]. The intent is that companies
share the financial risk of payers to reimburse the drug,
and pay for the drug when an agreed volume or budget
is exceeded, or intended clinical outcomes are not
achieved. Taiwan could learn lessons from neighboring
countries adopting HTA and risk-sharing agreements to
address the challenge of high-cost medicines.
Conclusion
Taiwan’s Drug Reimbursement Scheme under its univer-
sal National Health Insurance has come a long way over
the last two decades. It is highly regarded particularly on
the basis of comprehensive drug coverage, minimal pa-
tient cost burden, and timely access to new medicines.
The NHI implemented multiple policy changes to en-
hance rational use of drugs and to contain increasing
pharmaceutical expenditures. However, while the data
are limited, there were opposition from consumers and
physicians for some of the changes. Many policy changes
remain to be evaluated for their impacts on medication
use, quality of care, and pharmaceutical expenditures.
Further policy changes may be needed and these should
be developed in light of lessons learned by other coun-
tries that are also facing similar challenges. Stakeholders
(i.e., patients, clinicians, government, industry) need to
work closely together to continue to improve rational
use of drugs, the quality of healthcare, and the financial
sustainability of the National Health Insurance. Evidence-
informed policy changes with appropriate stakeholder en-
gagement will be important for optimal patient outcomes.
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